Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the maximum tolerated dose, the activity and the
safety profile of the combination of vorinostat and topotecan in patients with recurrent
small cell lung cancer